Thyroid and Parathyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
College of Life Sciences, Sichuan University, Chengdu, Sichuan, China.
Endocrinology. 2021 Mar 1;162(3). doi: 10.1210/endocr/bqab004.
The novel coronavirus disease 2019 (COVID-19) produced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sweeping the world in a very short time. Although much has been learned about the clinical course, prognostic inflammatory markers, and disease complications of COVID-19, the potential interaction between SARS-CoV-2 and the thyroid is poorly understood. In contrast to SARS-CoV-1, limited available evidence indicates there is no pathological evidence of thyroid injury caused by SARS-CoV-2. However, subacute thyroiditis caused by SARS-CoV-2 has been reported for the first time. Thyroid dysfunction is common in patients with COVID-19 infection. By contrast, certain thyroid diseases may have a negative impact on the prevention and control of COVID-19. In addition, some anti-COVID-19 agents may cause thyroid injury or affect its metabolism. COVID-19 and thyroid disease may mutually aggravate the disease burden. Patients with SARS-CoV-2 infection should not ignore the effect on thyroid function, especially when there are obvious related symptoms. In addition, patients with thyroid diseases should follow specific management principles during the epidemic period.
由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年新型冠状病毒病（COVID-19）在很短的时间内席卷全球。尽管已经了解了 COVID-19 的临床过程、预后炎症标志物和疾病并发症，但 SARS-CoV-2 与甲状腺之间的潜在相互作用仍知之甚少。与 SARS-CoV-1 不同，有限的现有证据表明，SARS-CoV-2 没有引起甲状腺损伤的病理证据。然而，首例由 SARS-CoV-2 引起的亚急性甲状腺炎已被报道。COVID-19 感染患者中甲状腺功能障碍很常见。相比之下，某些甲状腺疾病可能对 COVID-19 的预防和控制产生负面影响。此外，一些抗 COVID-19 药物可能会导致甲状腺损伤或影响其代谢。COVID-19 和甲状腺疾病可能会相互加重疾病负担。SARS-CoV-2 感染患者不应忽视对甲状腺功能的影响，尤其是当出现明显相关症状时。此外，在流行期间，甲状腺疾病患者应遵循特定的管理原则。
